Neuregulin modulates hormone receptor levels in breast cancer through concerted action on multiple signaling pathways
Clinical Science · 2023
DOI: 10.1042/cs20220472 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Science, 2023. Verfasst von Sheila Almaraz Postigo und 1 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biomedical Research of Salamanca (IBSAL), Instituto de Biología Molecular y Celular del Cáncer (CSIC-Universidad de Salamanca) and CIBER…. Hauptthemen laut MEDLINE: Neuregulins, Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The Neuregulins (NRGs) are growth factors that bind and activate ErbB/HER receptor tyrosine kinases. Some reports have described an interplay between this ligand–receptor system and hormonal receptors in breast cancer. However, the mechanisms by which NRGs regulate hormonal receptor signaling have not been sufficiently described. Here, we show that in breast cancer cells the activation of NRG receptors down-regulated ERα through a double mechanism that included post-transcriptional and transcriptional effects. This regulation required the concerted participation of three signaling routes: the PI3K/AKT/mTOR, ERK1/2, and ERK5 pathways. Moreover, these three routes were also involved in the phosphorylation of ERα at serines 118 and 167, two residues implicated in resistance to endocrine therapies. On the other hand, NRGs conferred resistance to fulvestrant in breast cancer cells and this resistance could be reversed when the three pathways activated by NRGs were simultaneously inhibited. Our results indicate that estrogen receptor-positive (ER+) breast tumors that can have access to NRGs may be resistant to fulvestrant. This resistance could be overcome if strategies to target the three main pathways involved in the interplay between NRG receptors and ERα could be developed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Biomedical Research of Salamanca (IBSAL), Instituto de Biología Molecular y Celular del Cáncer (CSIC-Universidad de Salamanca) and CIBERONC, Salamanca, Spain.
- Department of Pathology and IBSAL, University Hospital of Salamanca, University of Salamanca, 37007 Salamanca, Spain.
ORCID-Profile: Juan Carlos Montero
Zitieren
APA
Almaraz Postigo, S., & Montero, J. C. (2023). Neuregulin modulates hormone receptor levels in breast cancer through concerted action on multiple signaling pathways. Clinical Science. https://doi.org/10.1042/cs20220472
Vancouver
Almaraz Postigo S, Montero JC. Neuregulin modulates hormone receptor levels in breast cancer through concerted action on multiple signaling pathways. Clinical Science. 2023. doi:10.1042/cs20220472
BibTeX
@article{AlmarazPostigo2023,
author = {Almaraz Postigo, Sheila and Montero, Juan Carlos},
title = {Neuregulin modulates hormone receptor levels in breast cancer through concerted action on multiple signaling pathways},
journal = {Clinical Science},
year = {2023},
doi = {10.1042/cs20220472}
}
EUVIMED